| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532; 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:CDK2 inhibitor II
CAS:222035-13-4
Package:10Mg,50Mg,5Mg
|
| Company Name: |
VDM Biochemicals
|
| Tel: |
0330-2528181 |
| Email: |
sales@vdmbio.com |
| Products Intro: |
Product Name:Cdk2 Inhibitor II
CAS:222035-13-4
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:CDK2 Inhibitor II
CAS:222035-13-4
Purity:>=95% Remarks:Reach out to us for more information about custom solutions.
|
|
| | CDK2 INHIBITOR II Basic information |
| | CDK2 INHIBITOR II Chemical Properties |
| Melting point | >272°C (dec.) | | density | 1.85±0.1 g/cm3(Predicted) | | storage temp. | Amber Vial, -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly, Heated) | | form | Solid | | pka | 8.81±0.20(Predicted) | | color | Light Orange to Orange | | InChI | InChI=1S/C14H11BrN4O3S/c15-8-1-6-12-11(7-8)13(14(20)17-12)19-18-9-2-4-10(5-3-9)23(16,21)22/h1-7,18H,(H2,16,21,22)(H,17,19,20) | | InChIKey | ODZNNZYRBRRREX-UHFFFAOYSA-N | | SMILES | C1(S(N)(=O)=O)=CC=C(NN=C2C3=C(NC2=O)C=CC(Br)=C3)C=C1 |
| | CDK2 INHIBITOR II Usage And Synthesis |
| Description | The cyclin-dependent kinase 2 (Cdk2) works with cyclins A or E to regulate S phase and G2-M transition during the cell cycle. Cdk2 Inhibitor II is a 3-(benzylidne)indolin-2-one analog that selectively and potently inhibits Cdk2 (IC50 = 60 nM). It is cell permeable, reversible, and ATP-competitive. | | Uses | CDK2 inhibitor II, is a potent, cell-permeable, ATP-competitive, and selective inhibitor of Cdk2. | | in vivo | CDK2-IN-3 (2.5-250 μg, topical application, once daily, for 1 week) significantly reduces the incidence of alopecia in neonatal rat model induced by the combination of cyclophosphamide (HY-17420) and doxorubicin (HY-15142A)[1]. | Animal Model: | Cyclophosphamide (HY-17420)-Doxorubicin (HY-15142A) combination chemotherapy-induced alopecia neonatal Sprague-Dawley rat model (13 days) | | Dosage: | 2.5-250 μg | | Administration: | Topical application, once daily for 1 week | | Result: | Effectively prevented alopecia in 50% of rats and provided partial protection in an additional 20%. |
| | IC 50 | CDK2: 60 nM (IC50) | | References | [1] FUNK J. Cell Cycle Checkpoint Genes and Cancer[C]. 2006: 0. DOI: 10.1038/npg.els.0006046
[2] STEPHEN T. DAVIS, JR. Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors[J]. Science, 2001, 291 5501. DOI: 10.1126/science.291.5501.134 |
| | CDK2 INHIBITOR II Preparation Products And Raw materials |
|